Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 6/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677258 | 1.00 | GRM1 (0.39) | GRM1ATMALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL22507523 | 1.00 | GRM1 (0.39) | GRM1ATMALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL76360 | 1.00 | GRM1 (0.39) | GRM1ATMALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL2627957 | 0.88 | ALDH1A1 (0.38) | GRM1ALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL2739891 | 0.84 | GRM1 (0.38) | GRM1ATMEPHX2CYP19A1MAPT | |
| SCHEMBL14318437 | 0.83 | GRM1 (0.38) | GRM1ATMEPHX2CYP19A1MAPT | |
| SCHEMBL19480323 | 0.80 | GRM1 (0.33) | GRM1 | |
| SCHEMBL14619689 | 0.79 | PPP5C (0.36) | GRM1ATMSMN1; SMN2CYP19A1MAPT | |
| SCHEMBL2739878 | 0.78 | ATM (0.36) | GRM1ATMCYP19A1MAPTPDGFRB | |
| SCHEMBL5164652 | 0.78 | GBA1 (0.39) | GRM1ATMALDH1A1EPHX2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095047-A1 | Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors | UNIVERSITY OF CONNECTICUT (US) | 2012-04-19 | — | — | US | disclosed |
| US-8084451-B2 | Heteropyrrole analogs acting on cannabinoid receptors | UNIVERSITY OF CONNECTICUT (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100063050-A1 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINOID RECEPTORS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095047-A1 | Novel Heteropyrrole Analogs Acting on Cannabinoid Receptors | CNR2, CNR1, GPR18 | GRM1 177/4885ATM 3430/4885ALDH1A1 3880/4885 |
| US-20100063050-A1 | NOVEL HETEROPYRROLE ANALOGS ACTING ON CANNABINOID RECEPTORS | CNR2, CNR1, GPR18 | GRM1 177/4885ATM 3430/4885ALDH1A1 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.